Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

Enanta Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: MRSA, SSTI

Treatments: Drug: EDP-322

Study type: Interventional

Funder types: Industry

Identifiers

NCT00990145

EDP-322-07-002

Details and patient eligibility

About

This was a Phase I, single-center, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of orally administered EDP-322 in healthy adult volunteers.

Full description

Fifty-two subjects were enrolled into 6 cohorts. Six subjects of each cohort were randomized to received EDP-322 and 2 subjects of each cohort received placebo. Each cohort received the study drug once daily (QD) for 7 days under fed conditions. Multiple oral doses of EDP 322 ranging from 200 to 800 mg were safe and generally well tolerated by the healthy male and female subjects in this study.

Enrollment: 52 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult males or females between 18 and 45 years of age
• Females are eligible if documentation exists that they are surgically sterilized
• In good general health [determined by medical history, physical examination, clinical laboratory tests, and without evidence of a clinically significant abnormality, in the opinion of the investigator and medical monitor.
• Subject has a resting 12-lead ECG at screening that shows no clinically significant abnormality and a Bazett-corrected QT interval less than 450 milliseconds.
• BMI between 18-32 kg/m2
• Subject read, understood, and signed the ICF

Exclusion criteria

• History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, CNS, hematologic or metabolic disease, or has an immunologic, emotional, and/or psychiatric disturbance.
• History of gastric surgery, etc.
• Abnormality or clinical lab test results at Screening that is considered clinical significant by the investigator or the medical monitor.
• Gastroenteritis within 1 week before Day 1.
• Acute illness that could pose a threat or harm to the subject or interfere with laboratory test results or interpretation of study data.
• Donated blood within a 4 week period before Day 1.
• Positive for Hep B, C or HIV-1, HIV=2, or positive results at Screening for hepatitis B surface antigen (HBsAG), HCV antibody, or HIV-1 or HIV-2 antibodies
• Medication-related exclusions

Trial design

52 participants in 1 patient group

Intervention

Experimental group

Description:

EDP-322 v. Placebo

Treatment:

Drug: EDP-322